tiprankstipranks
Trending News
More News >
SciSparc Ltd. (SPRC)
:SPRC
US Market
Advertisement

SciSparc Ltd. (SPRC) Price & Analysis

Compare
185 Followers

SPRC Stock Chart & Stats


SciSparc Ltd. News

SPRC FAQ

What was SciSparc Ltd.’s price range in the past 12 months?
SciSparc Ltd. lowest stock price was $4.15 and its highest was $37.59 in the past 12 months.
    What is SciSparc Ltd.’s market cap?
    SciSparc Ltd.’s market cap is $3.91M.
      When is SciSparc Ltd.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were SciSparc Ltd.’s earnings last quarter?
      Currently, no data Available
      Is SciSparc Ltd. overvalued?
      According to Wall Street analysts SciSparc Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does SciSparc Ltd. pay dividends?
        SciSparc Ltd. does not currently pay dividends.
        What is SciSparc Ltd.’s EPS estimate?
        SciSparc Ltd.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does SciSparc Ltd. have?
        SciSparc Ltd. has 534,600 shares outstanding.
          What happened to SciSparc Ltd.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of SciSparc Ltd.?
          Currently, no hedge funds are holding shares in SPRC

          SciSparc Ltd. Stock Smart Score

          Company Description

          SciSparc Ltd.

          SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

          SciSparc Ltd. (SPRC) Earnings & Revenues

          Currently, no data available
          Please return soon. This page is being updated.
          Similar Stocks
          Company
          Price & Change
          Follow
          Galmed Pharmaceuticals
          InMed Pharmaceuticals
          Enveric Biosciences
          Artelo Biosciences
          Tao Synergies

          Ownership Overview

          0.61%99.39%
          Insiders
          Mutual Funds
          0.61% Other Institutional Investors
          99.39% Public Companies and Individual Investors

          Options Prices

          Currently, No data available
          ---
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis